DEA issues 4th extension of telehealth controlled substance flexibilities as debate enters 6th year - Fierce Healthcare
DEA extends telehealth flexibilities for controlled substance prescribing through December 31, 2025, maintaining current allowances without new restrictions.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 18, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: December 31, 2025. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The DEA issued a fourth extension of telehealth flexibilities for prescribing controlled substances, now valid until December 31, 2025. No new requirements or restrictions were added.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
No immediate action required. Continue current telehealth prescribing practices under existing flexibilities.
Deadline
December 31, 2025
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- DEA Adds Second Step to Reporting Procedure for Controlled Substance Theft or Loss - Reed Smith LLP
- Murphy signs bill scheduling tianeptine as Schedule II controlled substance in New Jersey - WRNJ Radio
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- US-CONGRESS HR7895: PBM Kickback Prohibition Act
- IL HB0004: MEDICAID-PHARMACY SERVICES